Prevalence of measurable disease in metastatic castration resistant prostate cancer

Abstract Background Given the low historical prevalence of measurable disease in metastatic castration-resistant prostate cancer (mCRPC), phase II trials have employed prostate specific antigen (PSA) and bone scan changes as primary endpoints. Frequent whole body imaging and improved computerized to...

Full description

Saved in:
Bibliographic Details
Published in:Clinical genitourinary cancer 2017-10, Vol.15 (5), p.534-539
Main Authors: Sonpavde, G, Madan, A, Baker, M.K, May, J.E, Naik, G, Bae, S
Format: Article
Language:English
Subjects:
Castration-resistant
Clinical Trials as Topic
Hematology, Oncology and Palliative Medicine
Humans
Male
Measurable tumor
Metastatic
Neoplasm Metastasis
Prevalence
Prostate cancer
Prostate-Specific Antigen - metabolism
Prostatic Neoplasms, Castration-Resistant - diagnosis
Prostatic Neoplasms, Castration-Resistant - epidemiology
Prostatic Neoplasms, Castration-Resistant - metabolism
RECIST
Tomography, X-Ray Computed
Urology
Whole Body Imaging - methods
Citations: Items that this one cites
Items that cite this one
Online Access:Get full text
Tags: Add Tag
No Tags, Be the first to tag this record!
Description
Summary:Abstract Background Given the low historical prevalence of measurable disease in metastatic castration-resistant prostate cancer (mCRPC), phase II trials have employed prostate specific antigen (PSA) and bone scan changes as primary endpoints. Frequent whole body imaging and improved computerized tomography technology currently identify measurable disease more frequently, warranting consideration of objective response as a major endpoint. Methods Data from reported phase III trials of mCRPC were analyzed. The proportion of patients with measurable disease, setting (pre-docetaxel [D], D-based, post-D), year of starting accrual, PSA, and the requirement for symptoms were collected. Chi-square test was used to evaluate the association of variables with measurable disease rate. Results Twenty phase III trials totaling 19,276 men with mCRPC were evaluable. Three trials (N=1289) started accruing before 2000 and 17 trials (N=17,987) accrued after 2000. The proportion of measurable disease rate for all trials was 47.5%. The measurable disease rate was significantly higher (p
ISSN:1558-7673
1938-0682
DOI:10.1016/j.clgc.2017.04.020